Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [847]

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )

Evaluating emerging mutations in patients with acute myeloid leukaemia who...

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )

Simplifying molecular subtypes of metastatic gastric cancer

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Appraising an NTRK testing algorithm: When, what, how

Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca

Appraising an NTRK testing algorithm: When, what, how ( Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca )

Oncogenomics: From a surgical perspective

Dr Gonzalo Ziegler - Clínica Ziegler, Lima, Perú

Oncogenomics: From a surgical perspective ( Dr Gonzalo Ziegler - Clínica Ziegler, Lima, Perú )

Using ctDNA to predict recurrence and response in colorectal cancer

Dr Aparna Parikh - Massachusetts General Hospital Cancer Center, Boston, USA

Using ctDNA to predict recurrence and response in colorectal cancer ( Dr Aparna Parikh - Massachusetts General Hospital Cancer Center, Boston, USA )

SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in...

Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA

SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC ( Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA )

Oncobox, RNA sequencing and molecular pathway analysis-base system for...

Dr Anton Buzdin - Sechenov Moscow First Medical University, Moscow, Russia

Oncobox, RNA sequencing and molecular pathway analysis-base system for prescription of target drugs to advanced cancer patients ( Dr Anton Buzdin - Sechenov Moscow First Medical University, Moscow, Russia )

More from ecancer